1,855 reports of this reaction
4.1% of all PIPERACILLIN SODIUM,TAZOBACTAM SODIUM reports
#3 most reported adverse reaction
ACUTE KIDNEY INJURY is the #3 most commonly reported adverse reaction for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, manufactured by Fresenius Kabi USA, LLC. There are 1,855 FDA adverse event reports linking PIPERACILLIN SODIUM,TAZOBACTAM SODIUM to ACUTE KIDNEY INJURY. This represents approximately 4.1% of all 44,977 adverse event reports for this drug.
Patients taking PIPERACILLIN SODIUM,TAZOBACTAM SODIUM who experience acute kidney injury should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACUTE KIDNEY INJURY is moderately reported among PIPERACILLIN SODIUM,TAZOBACTAM SODIUM users, representing a notable but not dominant share of adverse events.
In addition to acute kidney injury, the following adverse reactions have been reported for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM:
The following drugs have also been linked to acute kidney injury in FDA adverse event reports:
ACUTE KIDNEY INJURY has been reported as an adverse event in 1,855 FDA reports for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACUTE KIDNEY INJURY accounts for approximately 4.1% of all adverse event reports for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, making it one of the most commonly reported side effect.
If you experience acute kidney injury while taking PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.